It is well established that the 5-year survival rate for CRC, is greater than 90% when detected early²

Missed detection of early-stage CRC results in poor survival rates^3-5

Stage I - II

91%

Stage III

72%

Stage IV

13%

Risk factors associated with CRC

A risk factor is any factor that may increase a person’s possibility of developing cancer. Some risk factors are referred to as modifiable, such as lifestyle or environmental risk factors. Others are called non-modifiable, such as inherited factors or whether someone in the family has had cancer.⁶

The cause of colorectal cancer is not known. Evaluating your risk factors and discussing them with the doctor may help you make more informed lifestyle and health care choices.⁶

Modifiable Risk Factors⁶

A diet low in fibre

High red meat consumption, especially processed meats

Physical inactivity and obesity

Consumption of alcohol and tobacco

Low blood level of vitamin D

Non-Modifiable Risk Factors⁶

Personal history of certain types of cancers (ovarian/uterine)

IBD, such as Crohn’s and Ulcerative Colitis

Family history of CRC

Type 2 Diabetes

Aged ≥ 50

A previous diagnosis of polyps/CRC

Participation in CRC screening remains suboptimal despite national programs being in place in many countries worldwide.

In Australia, over 50% of eligible individuals remain unscreened for CRC, and this has not changed since the national program was introduced in 2006.⁷

Observational studies have shown that 78-93% of people offered CRC screening, preferred blood-based tests over faecal tests, with ease and convenience being the main reason for their preference.^2,8

Reasons for preferring blood-based options:^2,8

Convenience of a blood draw
Ease / comfort of a blood test
Lower time requirement vs faecal test

Rhythm Biosciences has developed ColoSTAT^®*, a simple, affordable blood-based test for the detection of CRC, is currently being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards.

*currently not approved for use in Australia

1

Standard blood draw at laboratory / collection centre (with referral)

2

Blood sample analysed at laboratory

3

Result sent to GP

4

GP follow-up with patient

SIMPLE – A blood test that is an easy addition to the standard panel of doctor requests. It is designed for easy adaptation by laboratories performing ELISA assays routinely.

ACCURATE – obtains a qualitative likelihood of CRC presence based on 5 protein biomarker levels in the blood.

PATIENT-FRIENDLY – convenient and can be part of routine health control.

ColoSTAT^® has the potential to:

Provide an alternative for those unwilling or unable to participate in current screening programs
Increase participation rate in CRC testing
Improve early diagnosis of CRC
Improve survival rates
Reduce mortality rate
Reduce healthcare costs associated with CRC treatment

ColoSTAT^® immunoassay test does not diagnose colorectal cancer but is a tool for determining when colonoscopy or another type of diagnostic follow-up is recommended.

RHY-001 study,⁹ evaluated ColoSTAT®'s clinical performance, versus the gold standard, Colonoscopy, and showed an estimated sensitivity of 81.3% and specificity of 91% (overall CRC)

Sensitivity⁹

81.3%

Specificity⁹

91%

References

https://www.cancer.net/cancer-types/colorectal-cancer/risk-factors-and-prevention#:~:text=About%2011%25%20of%20all%20colorectal,cancer%20in%20the%20United%20States
Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014 Oct 17;14:183
Australia colorectal cancer statistics. Available at: https://ncci.canceraustralia.gov.au/diagnosis/distribution-cancer-stage/distribution-cancer-stage
UK colorectal cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival#heading-Three
US colorectal cancer statistics. Available at : https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
https://www.canceraustralia.gov.au/cancer-types/bowel-cancer/awareness
National Cancer Control Indicators - https://ncci.canceraustralia.gov.au/screening/colorectal-screening-rates/colorectal-screening-rate-participation
Liles EG, Coronado GD, Perrin N, Harte AH, Nungesser R, Quigley N, Potter NT, Weiss G, Koenig T, deVos T. screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications. 2017 10: 27-31
Data on file, October 2021

11% of people diagnosed with Colorectal Cancer (CRC) are below the age of 50¹

It is well established that the 5-year survival rate for CRC, is greater than 90% when detected early²

Missed detection of early-stage CRC results in poor survival rates^3-5

91%

72%

13%

Risk factors associated with CRC

Rhythm Biosciences has developed ColoSTAT^®*, a simple, affordable blood-based test for the detection of CRC, is currently being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards.

RHY-001 study,⁹ evaluated ColoSTAT®'s clinical performance, versus the gold standard, Colonoscopy, and showed an estimated sensitivity of 81.3% and specificity of 91% (overall CRC)

Sensitivity⁹

81.3%

Specificity⁹

91%

About us:

Contact

Rhythm Biosciences

Keep up to date:

Connect with us:

11% of people diagnosed with Colorectal Cancer (CRC) are below the age of 501

It is well established that the 5-year survival rate for CRC, is greater than 90% when detected early2

Missed detection of early-stage CRC results in poor survival rates3-5

91%

72%

13%

Risk factors associated with CRC

Rhythm Biosciences has developed ColoSTAT®*, a simple, affordable blood-based test for the detection of CRC, is currently being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards.

RHY-001 study,9 evaluated ColoSTAT®'s clinical performance, versus the gold standard, Colonoscopy, and showed an estimated sensitivity of 81.3% and specificity of 91% (overall CRC)

Sensitivity9

81.3%

Specificity9

91%

About us:

Contact

Rhythm Biosciences

Keep up to date:

Connect with us:

11% of people diagnosed with Colorectal Cancer (CRC) are below the age of 50¹

It is well established that the 5-year survival rate for CRC, is greater than 90% when detected early²

Missed detection of early-stage CRC results in poor survival rates^3-5

Rhythm Biosciences has developed ColoSTAT^®*, a simple, affordable blood-based test for the detection of CRC, is currently being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards.

RHY-001 study,⁹ evaluated ColoSTAT®'s clinical performance, versus the gold standard, Colonoscopy, and showed an estimated sensitivity of 81.3% and specificity of 91% (overall CRC)

Sensitivity⁹

Specificity⁹